Axovant Sciences (AXON) – Investment Analysts’ Weekly Ratings Changes

A number of firms have modified their ratings and price targets on shares of Axovant Sciences (NASDAQ: AXON) recently:

  • 11/22/2017 – Axovant Sciences was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 11/12/2017 – Axovant Sciences had its “hold” rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
  • 11/10/2017 – Axovant Sciences had its “hold” rating reaffirmed by analysts at Piper Jaffray Companies.
  • 11/9/2017 – Axovant Sciences was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Axovant Sciences Ltd. is a biopharmaceutical company which focuses on the acquisition, development and commercialization of therapeutics for the treatment of neurodegenerative disorders. Its product candidate includes RVT-101 which is in different clinical trial for the treatment of Alzheimer’s disease and other forms of dementia. Axovant Sciences Ltd. is based in Hamilton, Bermuda. “
  • 11/3/2017 – Axovant Sciences had its “sell” rating reaffirmed by analysts at Chardan Capital. They now have a $3.00 price target on the stock.
  • 11/1/2017 – Axovant Sciences had its “hold” rating reaffirmed by analysts at Robert W. Baird. They now have a $6.00 price target on the stock.
  • 10/19/2017 – Axovant Sciences had its “buy” rating reaffirmed by analysts at HC Wainwright. They wrote, “We hosted a conference call with a medical physicist on October 17, 2017. The consultant highlighted a number of key benefits associated with ViewRay’s MRI-Cobalt and MRI-LINAC as well as main differences between ViewRay’s low-T MRIdian technology and competitor Elekta’s yet-to-be approved High- T Unity system. Replay information available upon request. KeyPoints High-T vs. Low-T. While in the context of a diagnosis, a high-T system would surely lead to greater image resolution, the low-T system appears more suitable in the treatment phase where the key lies in the ability to locate the patient’s tumor in a dynamic way. Image quality, it turns out, can be improved through various techniques according to our consultant.””
  • 10/17/2017 – Axovant Sciences was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 10/9/2017 – Axovant Sciences was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “strong-buy” rating. They now have a $8.00 price target on the stock. According to Zacks, “Axovant Sciences Ltd. is a biopharmaceutical company which focuses on the acquisition, development and commercialization of therapeutics for the treatment of neurodegenerative disorders. Its product candidate includes RVT-101 which is in different clinical trial for the treatment of Alzheimer’s disease and other forms of dementia. Axovant Sciences Ltd. is based in Hamilton, Bermuda. “
  • 10/6/2017 – Axovant Sciences had its “sell” rating reaffirmed by analysts at Chardan Capital. They now have a $3.00 price target on the stock.
  • 10/5/2017 – Axovant Sciences was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 9/27/2017 – Axovant Sciences had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.
  • 9/27/2017 – Axovant Sciences had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $12.00 price target on the stock.
  • 9/26/2017 – Axovant Sciences was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 9/26/2017 – Axovant Sciences had its “outperform” rating reaffirmed by analysts at Evercore ISI. They now have a $9.00 price target on the stock, down previously from $30.00.
  • 9/26/2017 – Axovant Sciences had its “outperform” rating reaffirmed by analysts at Cowen Inc. They now have a $25.00 price target on the stock, down previously from $30.00.
  • 9/26/2017 – Axovant Sciences was downgraded by analysts at Oppenheimer Holdings, Inc. from an “outperform” rating to a “market perform” rating.
  • 9/26/2017 – Axovant Sciences had its “outperform” rating reaffirmed by analysts at JMP Securities. They now have a $19.00 price target on the stock, down previously from $36.00.
  • 9/26/2017 – Axovant Sciences was downgraded by analysts at Piper Jaffray Companies from an “overweight” rating to a “neutral” rating. They now have a $9.00 price target on the stock, down previously from $32.00.
  • 9/26/2017 – Axovant Sciences was downgraded by analysts at UBS AG from an “outperform” rating to a “market perform” rating.
  • 9/26/2017 – Axovant Sciences was downgraded by analysts at Robert W. Baird from an “outperform” rating to a “neutral” rating. They now have a $6.00 price target on the stock, down previously from $29.00.
  • 9/25/2017 – Axovant Sciences had its “buy” rating reaffirmed by analysts at Oppenheimer Holdings, Inc.. They now have a $30.00 price target on the stock.

Shares of Axovant Sciences Ltd. (NASDAQ AXON) traded down $0.24 on Friday, hitting $5.41. The stock had a trading volume of 393,371 shares, compared to its average volume of 1,026,770. The company has a current ratio of 5.94, a quick ratio of 5.94 and a debt-to-equity ratio of 0.34. Axovant Sciences Ltd. has a 52 week low of $4.60 and a 52 week high of $27.98.

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Receive News & Ratings for Axovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2017 Ticker Report. Google+.